TheraRadar
← Back
Data updated: Jun 28, 2026

ASCENT PHARMS INC

Generics

ASCENT PHARMS INC is a generic drug manufacturer focused on Oncology, Neurology, Metabolic.

2015
Since
39
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

ASCENT PHARMS INC's Key Drugs

ASCENT PHARMS INC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, IBUPROFEN AND FAMOTIDINE, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.

ASCENT PHARMS INC's Therapeutic Areas

ASCENT PHARMS INC's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 40%
2 drugs
Neurology 20%
1 drugs
Metabolic 20%
1 drugs
Cardiovascular 20%
1 drugs

ASCENT PHARMS INC's Top Competitors

ASCENT PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ASCENT PHARMS INC Pipeline Snapshot

Active clinical trials for ASCENT PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling